These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 23052656

  • 1. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K.
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [Abstract] [Full Text] [Related]

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
    BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
    [Abstract] [Full Text] [Related]

  • 3. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
    [Abstract] [Full Text] [Related]

  • 4. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T.
    Clin Exp Nephrol; 2017 Aug 04; 21(4):671-676. PubMed ID: 27558467
    [Abstract] [Full Text] [Related]

  • 5. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K.
    Pediatr Nephrol; 2011 Oct 04; 26(10):1823-8. PubMed ID: 21556716
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
    Sun L, Xu H, Shen Q, Cao Q, Rao J, Liu HM, Fang XY, Zhou LJ.
    World J Pediatr; 2014 Feb 04; 10(1):59-63. PubMed ID: 24464665
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Pediatr Nephrol; 2017 Nov 04; 32(11):2071-2078. PubMed ID: 28664242
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S.
    Pediatr Nephrol; 2016 Jan 04; 31(1):89-95. PubMed ID: 26341251
    [Abstract] [Full Text] [Related]

  • 9. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K.
    BMC Nephrol; 2019 Aug 02; 20(1):293. PubMed ID: 31375087
    [Abstract] [Full Text] [Related]

  • 10. Association between the time of initial relapse and subsequent relapses in patients with childhood-onset idiopathic nephrotic syndrome.
    Inoki Y, Nishi K, Osaka K, Kaneda T, Akiyama M, Sato M, Ogura M, Kamei K.
    Pediatr Nephrol; 2024 Aug 02; 39(8):2393-2401. PubMed ID: 38267591
    [Abstract] [Full Text] [Related]

  • 11. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
    Health Technol Assess; 2019 May 02; 23(26):1-108. PubMed ID: 31156083
    [Abstract] [Full Text] [Related]

  • 12. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome.
    Sato M, Ito S, Ogura M, Kamei K.
    Pediatr Nephrol; 2014 Aug 02; 29(8):1373-9. PubMed ID: 24599443
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T.
    Nephrol Dial Transplant; 2012 Mar 02; 27(3):1083-9. PubMed ID: 21810762
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
    Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y, Sakuraya K.
    Pediatr Nephrol; 2019 Feb 02; 34(2):353-357. PubMed ID: 30426219
    [Abstract] [Full Text] [Related]

  • 15. Rituximab for childhood refractory nephrotic syndrome.
    Iijima K.
    Pediatr Int; 2011 Oct 02; 53(5):617-621. PubMed ID: 21771179
    [Abstract] [Full Text] [Related]

  • 16. Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?
    Subun C, Suwannahitatorn P, Webb H, Tullus K.
    Arch Dis Child; 2021 Jul 19; 106(8):815-818. PubMed ID: 33177054
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.
    Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A.
    Clin J Am Soc Nephrol; 2010 Dec 19; 5(12):2207-12. PubMed ID: 20798255
    [Abstract] [Full Text] [Related]

  • 18. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.
    Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K.
    Pediatr Nephrol; 2010 Mar 19; 25(3):539-44. PubMed ID: 20049616
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.
    Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V, Cailliez M, Pietrement C, Dunand O, Nathanson S, Bertholet-Thomas A, Ichay L, Decramer S.
    Pediatr Nephrol; 2013 Jun 19; 28(6):911-8. PubMed ID: 23340857
    [Abstract] [Full Text] [Related]

  • 20. Rituximab for nephrotic syndrome in children.
    Iijima K, Sako M, Nozu K.
    Clin Exp Nephrol; 2017 Apr 19; 21(2):193-202. PubMed ID: 27422620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.